Revolution Medicines News and Activities
Presence
Revolution Medicines develops cancer medicines based on targeted drug discovery. It offers precision oncology drug candidates and research services for patients, healthcare providers, and pharmaceutical partners.
Revolution Medicines products and services overview:
- Cancer therapies
- Targeted medicines
- Drug discovery
- Research services
Revenue: ~$160 million
Employees: 500
Headquarters: Redwood City, United States (USA)
Revolution Medicines is one of the...
Revolution Medicines is a company listed under the stock ticker RVMD (US).
Executives
View the org chart displaying its 41 main executives
Most searched biographies at Revolution Medicines
- Mark Goldsmith, President, Chief Executive Officer and Board Chair...
- Lorence Kim, Director
- Thilo Schroeder, Director
Popular executive movements at Revolution Medicines
- Laurent Bride has joined the company as Chief Digital Officer (posted on December 31 2025).
- Alan Sandler has joined the company as Chief Development Officer (posted on October 1 2025).
Create your alert
to follow the executive moves at Revolution Medicines.
Pharmaceuticals
Revolution Medicines has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Revolution Medicines
- Press Releases | Revolution Medicines
- Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition | Revolution Medicines
- Revolution Medicines Completes Acquisition of EQRx | Revolution Medicines
- Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress | Revolution Medicines
- Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 | Revolution Medicines
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc. | Revolution Medicines
- Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 | Revolution Medicines
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast | Revolution Medicines, Inc.
- Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting | Revolution Medicines, Inc.
- Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor | Revolution Medicines, Inc.
- View more press releases Close
Social media about Revolution Medicines
- Revolution Medicines on Wikipedia, Google News & Yahoo Finance
- Revolution Medicines on LinkedIn, X (Twitter) & YouTube
